Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September – Biotech Investments
Issuer: Immunic AG / Key word(s): Conference 28.08.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Host